


Corbion results H1 2022



- Business performance
- Outlook



• Financial performance



H1 2022 Key Points

- Organic sales growth core activities 23.0%
 - Growth driven by all three business units
- Adjusted EBITDA: €89.9M (13.1% margin), organic growth -0.4%
- Inflationary cost developments ongoing Rapid pricing actions as response
- June was first break-even month for AlgaPrime DHA
- Continued high investment level to support growth
- Sustainability progress ahead of schedule Corbion Science Based Targets commitment increased to 1.5°C



Business developments

Sustainable Food Solutions

- Preservation:
 - Supporting customer recipes reformulations driven by cost inflation
 - Launch of new natural antioxidant platform
- Functional Systems:
 - Focus on shelf-life extension, Food ferments and reformulations driven by raw material shortages
 - Launch of new Dairy stabilizers platforms

Lactic Acid & Specialties

- Growth in all business segments
- Strong recovery in medical biopolymers post pandemic period
- Robust lactic acid sales to PLA over H1

Incubator

- Significant traction in new customers adoption of AlgaPrime DHA
- June was first break-even month for AlgaPrime DHA
- Higher variable costs (rapeseed, freight costs)









Major investment projects




New lactic acid plant

• Thailand, Rayong

• Total capex: \$ 230M

• Operational: H2 2023



SFS: natural ferments

• US, Peoria

• Total capex: € 10-15M

• Operational: End of 2022



Incubator: Algae fermentation

• Brazil, Orindiuva

• Total capex: € 10-15M

• Operational: End of 2022

Projects on schedule



Corbion raises commitment to 1.5°C, the most ambitious goal of the Paris Agreement





Financial performance





Profit and Loss

€ million	YTD	YTD		Q2	Q2	%
	2022	2021	%	2022	2021	
Net Sales	687.4	515.6	33.3%	367.3	264.1	39.1%
Adjusted EBITDA	89.9	77.1	16.6%	49.9	33.2	50.3%
EBITDA %	13.1%	15.0%		13.6%	12.6%	
Adjusted Depreciation & Amortization	(36.3)	(30.3)	19.8%	(19.0)	(15.5)	22.6%
Adjustments	5.5	23.5	-76.6%	(2.0)	(6.2)	-67.7%
EBIT	59.1	70.3	-15.9%	28.9	11.5	151.3%
Financial income/expenses	1.8	(5.9)	-130.5%	1.4	(2.3)	-160.9%
Result joint ventures/assoc.	8.9	10.4	-14.4%	4.1	5.4	-24.1%
Taxes	(18.0)	(7.3)	146.6%	(9.3)	(1.4)	564.3%
Result after tax	51.8	67.5	-23.3%	25.1	13.2	90.2%
EPS	0.88	1.15	-23.3%	0.43	0.22	89.9%



Firm pricing actions implemented

- We expect full compensation of higher input costs
 - In aggregate, input costs in 2021 and 2022 rise by € 240M (of which € 190M in Core)
 - Previous estimate: € 165M (of which € 130M in Core)
- Pricing contract structure more flexible
 - Majority of contracts moved from annual to quarterly pricing
 - Provides for faster price adjustments
- Firm pricing actions implemented
 - Already 3 quarterly pricing rounds in 2022
- Pricing actions have significant mathematical dilutive effect on margin


Additional raw materials, energy, packaging, freight increase

€ million	2021 vs 2020	2022 vs 2021	Cumulative
Core	40	150	190
Non-core	10	40	50
Total	50	190	240



Sustainable Food Solutions

€ million	YTD 2022	YTD 2021	Q2 2022	Q2 2021
Net sales	365.8	284.1	195.0	145.2
Organic growth	18.5%	15.5%	21.2%	18.7%
Adjusted EBITDA	44.7	39.7	24.9	16.5
Adjusted EBITDA margin	12.2%	14.0%	12.8%	11.4%



• Net sales organic growth of 18.5%

- Preservation
 - Price increases & mix improvements
 - Limited volume growth after strong market share gains in 2020/21
- Functional Systems
 - Volume growth driven by new product introductions & increased product usage
 - Supporting more customers with reformulations
- Single Ingredients: Deliberate shedding of some lower margin beverage (acidification) business


Adjusted EBITDA margin from 14.0% to 12.2%

- Lagging effect of implementing higher prices
- Dilutive effect of price increases on the margin
- 2021 investments in organizational capabilities in line with our Advance 2025 strategy



Lactic Acid & Specialties

€ million	YTD 2022	YTD 2021	Q2 2022	Q2 2021
Net sales	201.8	151.0	106.0	76.5
Organic growth	26.4%	12.6%	29.4%	25.2%
Adjusted EBITDA	39.6	33.1	19.9	14.8
Adjusted EBITDA margin	19.6%	21.9%	18.8%	19.3%



• Net sales organic growth of 26.4%

- All product segments grew significantly
- Notable growth segments: Lactic acid to PLA, Esters (semiconductor market), and medical biopolymers


Adjusted EBITDA margin from 21.9% to 19.6%

- Rising input costs not yet fully reflected in sales price
- Headcount increase related to lactic acid capacity expansion and medical biopolymers



Incubator

€ million	YTD 2022	YTD 2021	Q2 2022	Q2 2021
Net sales	24.1	11.8	14.5	6.6
Organic growth	87.3%	161.1%	98.5%	132.3%
Adjusted EBITDA	(8.5)	(6.8)	(3.7)	(3.4)
Adjusted EBITDA margin	-35.3%	-57.6%	-25.5%	-51.5%



- Net sales organic growth of 87.3%
 - Sales growth driven by AlgaPrime DHA (omega-3)
- Adjusted EBITDA loss increased from € -6.8 million to € -8.5 million
 - Higher variable costs
 - Raw materials and freight
 - Negative currency effect (strengthening of the Brazilian Real)
 - Partly offset by higher sales



TotalEnergies Corbion joint venture

€ million *	YTD 2022	YTD 2021	Q2 2022	Q2 2021
Net sales	91.9	75.0	43.8	37.9
EBITDA	30.1	27.5	14.4	11.6
EBITDA margin	32.7%	36.7%	32.9%	30.6%

^{*}Results on 100% basis. Corbion owns 50% of TotalEnergies Corbion joint venture

- Net sales growth of 22.5% through combination of price and volume growth
- EBITDA margin lower as higher input and freight costs and investments in organization offset positive operational leverage






Non-core activities

€ million	YTD 2022	YTD 2021	Q2 2022	Q2 2021
Net sales	95.7	68.7	51.8	35.8
Organic growth	26.3%	10.4%	28.5%	18.5%
Adjusted EBITDA	14.1	11.1	8.8	5.3
Adjusted EBITDA margin	14.7%	16.2%	17.0%	14.8%

- Net sales organic growth of 26.3% in Emulsifiers
 - Fully driven by price/mix improvements due to raw material profile
 - Slightly negative volumes after significant market share gains in 2021
- H1 margin pressure due to dilutive effect of price increases.
 Absolute EBITDA growth both in H1 and Q2, also supported by currency effects



Net debt bridge H1 2022



- Covenant net debt/covenant EBITDA increased from 2.6x to 3.3x
 - covenant net debt/covenant EBITDA is 3.75x



Outlook 2022

- Net sales organic growth core activities 20-25% (was: 15-20%)
- Input cost increase for core vs 2020 of € 190 million (was: € 130 million)
- Adjusted EBITDA margin core activities: lower end of 12-15% range (was: in 12-15% range)
 - higher dilutive effect on margin due to further price increases
 - on track to substantially improve absolute Adjusted EBITDA compared to last year
- Capital expenditures: € 200 230 million
- Covenant net debt/covenant EBITDA ratio improvement by year-end vs H1 (3.3x)



Annex



Net sales and Adjusted EBITDA: YTD/Q2 2022

€ million	YTD 2022	YTD 2021	Q2 2022	Q2 2021	Growth YTD
Net sales					
Core	591.7	446.9	315.5	228.3	32.4%
- Sustainable Food Solutions	365.8	284.1	195.0	145.2	28.8%
- Lactic Acid & Specialties	201.8	151.0	106.0	76.5	33.6%
- Incubator	24.1	11.8	14.5	6.6	104.2%
Non-core	95.7	68.7	51.8	35.8	39.3%
Total Net Sales	687.4	515.6	367.3	264.1	33.3%
Adjusted EBITDA					
Core	75.8	66.0	41.1	27.9	14.8%
- Sustainable Food Solutions	44.7	39.7	24.9	16.5	12.6%
- Lactic Acid & Specialties	39.6	33.1	19.9	14.8	19.6%
- Incubator	(8.5)	(6.8)	(3.7)	(3.4)	-25.0%
Non-core	14.1	11.1	8.8	5.3	27.0%
Total Adjusted EBITDA	89.9	77.1	49.9	33.2	16.6%




Sales growth per segment in YTD/Q2 2022

Net sales	Volume	Price/Mix	Organic	Currency	Acquisitions/ (Divestments)	Total growth
YTD 2022 vs YTD 2021						
Core	2.0%	21.0%	23.0%	9.2%	0.2%	32.4%
- Sustainable Food Solutions	0.1%	18.4%	18.5%	10.0%	0.3%	28.8%
- Lactic Acid & Specialties	1.1%	25.3%	26.4%	7.2%	0.0%	33.6%
- Incubator	72.5%	14.8%	87.3%	16.9%	0.0%	104.2%
Non-core	-2.6%	28.9%	26.3%	13.0%	0.0%	39.3%
Total	1.4%	22.0%	23.4%	9.7%	0.2%	33.3%
Q2 2022 vs Q2 2021						
Core	1.5%	24.6%	26.1%	11.8%	0.3%	38.2%
- Sustainable Food Solutions	0.4%	20.8%	21.2%	12.7%	0.4%	34.3%
- Lactic Acid & Specialties	-1.9%	31.3%	29.4%	9.2%	0.0%	38.6%
- Incubator	89.3%	9.2%	98.5%	21.2%	0.0%	119.7%
Non-core	-3.9%	32.4%	28.5%	16.2%	0.0%	44.7%
Total	0.8%	25.7%	26.5%	12.4%	0.2%	39.1%




Core Adjusted EBITDA bridge YTD 2022






Core Adjusted EBITDA bridge Q2 2022





Investments

Investments



Total investments H1 2022 € 99M

- Recurring capex € 48M (including expansion projects)
- New lactic acid plant (Thailand) € 46M

• Recurring capex includes


- Lactic acid expansion € 15M
- Natural ferments € 5M
- ERP investment € 4M

Capex outlook 2022

- 2022 estimated capex € 200-230M
- New lactic acid plant (Thailand), algae fermentation plant capacity (Brazil), natural ferments plant capacity (US)



Free Cash Flow



• Significant investment program

• New lactic acid plant in Thailand

Lower operating cashflow

- Increased working capital
 - inflationary input costs
 - safety stock buildup



Working capital (days)



- Increased Inventory days mainly caused by inflationary input costs and safety stock build up
- **Debtor** aging profile is stable





Investor relations





